RxDoctor Payments Data

Linda Powers, MD

Endocrinology, Diabetes & Metabolism · South Hill, VANPI 1013912583

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 88 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$586
  • Pfizer$174
  • Novo Nordisk$129
  • Amgen$80
  • GSK$53
  • AstraZeneca$36
  • plus $219 from 12 others

What the payments were for

  • Food & beverage$1,26399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,277 in reported general payments places this provider in the 45th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia

Medicare billing

Part B allowed, 2024
$423,776
Medicare patients
630
Services billed
11,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$265,832
JardianceEmpagliflozin242$239,539
EliquisApixaban221$208,847
MounjaroTirzepatide140$158,028
JanuviaSitagliptin Phosphate129$149,565
TradjentaLinagliptin213$134,987
Humulin R U-500 KwikpenInsulin Regular, Human131$118,397
FarxigaDapagliflozin Propanediol87$91,829
TrulicityDulaglutide61$78,438
ArexvyRsvpref3 Antigen/As01e/Pf226$69,617
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog65$48,509
Tresiba Flextouch U-200Insulin Degludec41$40,876
Lantus SolostarInsulin Glargine,hum.Rec.Anlog212$38,603
XareltoRivaroxaban37$37,140
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/729$36,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$129$279,142191 claims
Lilly USA, LLCMounjaro, Trulicity$11$236,466201 claims
PfizerEliquis$174$208,847221 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta$53$145,581409 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$36$113,961115 claims
AbbVieLinzess$586$34,94851 claims
Astellas Pharma US IncMyrbetriq$11$31,76846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

Other endocrinology, diabetes & metabolism in South Hill

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →